State Supreme Court Slaps Down Ducey’s Harmful Ban on Compulsory School Masking

It took the Arizona Supreme Court less than two hours last week to slap down the Legislature and Doug Ducey’s law micromanaging schools by prohibiting them from requiring masks indoors in classrooms. It was a unanimous ruling from the 7-judge court (the majority of the court has been appointed by Ducey).

The ruling means dozens of policies that were crammed into the budget reconciliation bills (BRBs) are now void (including the harmful micromanagement of K-12, university and community college mitigation measures).

The Court will release a detailed opinion that will become an important part of Arizona case law in the coming weeks. Doug Ducey, through his flack, described Cooper as a “rogue” judge interfering with the affairs of the executive and judicial branch. Perhaps he has forgotten the basics of civics?

Judge Cooper had ruled that Ducey’s ban on school mask requirements violates Arizona’s constitution because the Budget Reconciliation Bill (HB2898) that contained the harmful ban violates the Title Requirement of the Constitution- which says that the title of the Bill needs to reflect the contents therein.

Here are direct excerpts from the Superior Court Ruling:

The Arizona Supreme Court apprised the Legislature that the single subject and title requirements apply to budget-related bills. And, in Hoffman, the Court specifically stated the single subject rule applies to every act considered by the Legislature. Despite these warnings, the Legislature passed four budget reconciliation bills that fail to meet the constitutional requirements of Section 13. For the reasons stated, the Court finds that the BRBs violate the title requirement and SB1819 also violates the single subject rule.

Universities, K-12 schools, and community colleges can now ignore the anti-mitigation portions of those BRBs. Importantly, the Legislature will no longer be able to cram unelated pieces of legislation into budget bulls in the future. If they do, a lawsuit could quickly be filed, and any judge will be able to look at this Supreme Court ruling to quickly void a noncompliant law.

COVID Vaccine for Kids 5-11 Rolling Out

Things moved swiftly in the last week. FDA authorized the use Pfizer’s pediatric (10ug mRNA) vaccine, CDC’s Advisory Committee for Immunization Practices (ACIP) unanimously urged the CDC Director to recommend the vaccine, which she did late last week.

The vaccine comes in 10 dose vials with 30 vials to a box. Because HHS contracted with Pfizer for an adequate supply it won’t be necessary to use lower doses of the adult vaccine to immunize kids.

Providers and county health departments pre-ordered the vaccine over the last couple of weeks. Shipments began last Sunday with vaccine and the ancillary kits arriving last Tuesday.

Most Arizona county health departments are using pediatric practices and community health centers (medical homes) as the Plan A locations to vaccinate kids-. They are also organizing community events. Additionally, pharmacy chains are ordering and vaccinating.

Vaccines are free, and no identification, proof of residency, or insurance is required. Maricopa County has a complete list of vaccination sites on their website at www.Maricopa.gov/COVID19VaccineLocations. ADHS also has a website with the locations statewide: ADHS – Find COVID-19 Vaccines.

National data suggests that about 1/3 of parents plan to vaccinate their children as soon as the Pfizer-BioNTech vaccine becomes available. With about 600,000 kids aged 5-11 in Arizona, expect families of about 200,000 kids to seek vaccine in the first couple of weeks.

The pediatric Pfizer COVID-19 vaccine, which is one-third the dosage given to teens and adults, will still require two shots at least three weeks apart.  Vaccination of children age 5-11 with two doses is  91% effective in preventing symptomatic COVID-19.

Arizona’s Delta Wave Back on the Upswing

View Dr. Gerald’s Full Epidemiologic & Hospital Occupancy Report

From Dr. Joe Gerald this week:  The past 2 weeks has seen a reversal of past trends with cases rising 25% or more. The cause is uncertain. but the list of culprits includes fall break for many K – 12 schools, a welcomed cold front that cooled things downs for a week or so, waning vaccine and acquired immunity, sporting events, loss of individual mitigation behaviors.

Ultimately, these triggers don’t matter as much as our poor individual and collective efforts to do the hard work necessary to adapt to pandemic living: getting vaccinated, getting tested, wearing a mask, avoiding high risk exposures, and crafting GOOD public policy. Unlike the movies, in the real world, undisciplined teams with poor coaching get crushed, time and time again.

In that spirit, a new report to be published by the Arizona Public Health Association tomorrow shows that Arizona will hold the unique distinction as the only state where COVID-19 has been the leading cause of death during the pandemic.

The data are now overwhelming that vaccination doesn’t provide durable immunity to reinfection. If you are on the fence, now is the time to get your third shot booster! While protection against severe illness is more long-lasting it wanes as well. Check out the updated links in the attached report for a number of major publications this past week that shed light on the way forward with our vaccination strategy.

In a bit of good news, ADHS is making it possible for our 3 data teams (UA, ASU, and NAU) to link vaccine and case data. Hopefully, it will allow us to make more sense of conditions on the ground. A note of appreciation to Dr. Rich Carmona who advocated on our behalf in his new advisory role with the Governor’s office.

The Health Insurance Marketplace Is Now Open

The Health Insurance Marketplace (HealthCare.gov) where consumers can shop for comprehensive health insurance is open from November 1, 2021, to January 15, 2022. Arizonans have more insurance companies to choose from, new plans, and greater financial help. Because of the American Rescue Act, consumers will find several changes, including:

  • If taxable family income is not more than 150% of Federal Poverty Level ($32,940 family of 3) consumers can choose a plan with no monthly premium, plus reduced costs when you get medical care.
  • For consumers earning more than 400% Federal Poverty Level ($87,840 family of 3) they will not pay more than 8.5% of income for monthly premiums. This can save some higher income consumers thousands of dollars. Older Arizonans have higher monthly premiums than younger people and will benefit more than younger people. Older Arizonans with higher income may find coverage is more affordable than previous years.

For no-cost, unbiased, bilingual help from certified helpers” (Assisters and Navigators) Call 800.377.3536 or go to www.CoverAZ.org.

Pharma’s Big Con: Keep the Scam Going by Confusing Prescription Drug Prices with Out of Pocket Costs

For the last 20 years, all Americans have been getting ripped off by pharmaceutical companies.  The heist began way back when a prescription drug benefit was added for Medicare enrollees. Drug company lobbyists got Congress to write the law so that Medicare is prohibited from negotiating drug prices.

As a result, Medicare pays 300% more for prescription drugs than in Europe or Canada, and close to 10x higher than in developing nations. That means every American who gets a paycheck is paying way more than necessary for prescription drugs.

Why are we ALL being scammed (not just Medicare beneficiaries)? Simple: because Medicare is paid for by a payroll tax. Employers & employees each pay a 1.45% tax on wages up to $200,000 (2.9% total) into the Medicare Trust Fund. Individuals (not employers) pay a 0.9% tax on income above $200,000 per year (with no upper limit).

Because Medicare is paid for by a payroll tax, everybody who earns a paycheck is getting ripped off by drug companies- even if they’re not enrolled in Medicare and even if they don’t even take prescription drugs!

The gravy that the drug companies are taking from us is tremendously expensive. Last year, Medicare paid out $129 Billion dollars for prescription drugs. If Medicare were allowed to negotiate prices, taxpayers could save about $60B per year (enough to pay for dental and vision benefits for Medicare recipients).

Because healthcare costs in private health insurance plans is often driven by Medicare reimbursement, people in employer and other private health insurance plans are paying way too much too (resulting in higher monthly premiums).

Previous AzPHA Blog Posts on this Subject:

Fortunately, there’s a simple market-based solution. 

The president’s Build Back Better plan includes a provision that would save the federal government and everyday consumers billions of dollars per year by finally allowing Medicare to negotiate brand name drug prices with manufacturers.

The US House of Representatives already passed a measure called “H.R. 3, the Lower Drug Costs Now Act of 2019” which would require HHS to negotiate the price of between 25-125 brand-name drugs. That negotiated price would be available to Medicare, Medicaid and private payers.

It would establish an upper limit for the negotiated price equal to 120% of the Average International Market price paid by Australia, Canada, France, Germany, Japan, and the UK.

The plan would impose financial penalties on drug companies that don’t comply with the negotiating process. Manufacturers that fail to negotiate would face an escalating excise tax on the previous year’s gross sales of the drug in question, starting at 65% and increasing by 10% every quarter to a maximum of 95%.

There’s almost enough support in Congress to get this sorely needed reform done. Sadly, Senator Sinema appears to be a holdout on this provision of the Build Back Better plan.

The Big Con

The drug companies are trying to capture Senators on their big con: confuse the public and seniors by substituting a cosmetic plan to lower out-of-pocket costs at the pharmacy counter for Medicare enrollees rather than sticking with real drug pricing reform (allowing Medicare to negotiate).

Under the drug companies plan, prescription drug prices would appear to be lower because Medicare recipients would have lower co-pays. The scam is that that the Medicare Trust Fund would continue to pay 300% more than necessary for drugs. The Medicare Trust Fund would continue to be unnecessarily fleeced, and private health plans would also continue to pass along extra costs to their customers in the form of increased premiums.

It’s frustrating that even though 94% of the public supports this common-sense market-based reform (allowing Medicare to negotiate prices), it appears to have failed.

It’s easy to blame the drug company lobbyists, but the truth is that elected officials who sell out to the drug companies are the ones who have failed us.

November 2, 2021 Update:

Senator Sinema’s office released the following statement today suggesting that she is on board with the plan to allow Medicare to negotiate drug prices:

“After Senator Sinema reached earlier agreement with President Biden to include historic Medicare drug negotiation in the reconciliation package – policies that were omitted from the initial framework at the request of members of the U.S. House – Speaker Pelosi reached out to Senator Sinema this past weekend to continue negotiations.

The Senator welcomes a new agreement on a historic, transformative Medicare drug negotiation plan that will reduce out-of-pocket costs for seniors – ensuring drug prices cannot rise faster than inflation – save taxpayer dollars, and protect innovation to ensure Arizonans and Americans continue to have access to life-saving medications, and new cures and therapeutics. We also thank Representatives Peters and Schrader for their hard work securing this historic agreement.”

Now we need to make sure that the final deal has an effective enforcement mechanism to ensure that Pharma negotiates with Medicare in good faith, that a large or unlimited number of name brand drugs can be negotiated, and that the Medicare negotiated price can apply to private health insurance plans.

Critical Moment for Prescription Drug Price Relief

AzPHA Partners with Protect Our Care on Radio Ad Urging Sinema to Support Price Reform

It’s no secret that prescription drug prices in the U.S. are far higher than in other countries and that the current system costs taxpayers, insurance plans and people far more than it should. A huge barrier has been language in the Medicare law that prevents HHS from directly negotiating drug prices under the Medicare Part D drug benefit program. 

Achieving prescription drug pricing reform (allowing Medicare to negotiate drug prices) has been out of reach for decades because the drug company lobby is so powerful that meaningful reform has been impossible.

Whether we achieve pricing relief will depend on what happens in the next month. The president’s Build Back Better plan includes a provision that would save the federal government and everyday consumers Billions of dollars per year in perpetuity by finally allowing Medicare to negotiate brand name drug prices with manufacturers.

The US House of Representatives has already passed a measure called “H.R. 3, the Lower Drug Costs Now Act of 2019” which would require HHS to negotiate the price of between 25-125 brand-name drugs without generic competitors. That negotiated price would be available Medicare, Medicaid and private payers. Importantly, HR 3 also provides some negotiating leverage to HHS.

For one thing, it would establish an upper limit for the negotiated price equal to 120% of the Average International Market price paid by Australia, Canada, France, Germany, Japan, and the UK.

It would impose financial penalties on drug companies that don’t comply with the negotiating process. Manufacturers that fail to negotiate would face an escalating excise tax on the previous year’s gross sales of the drug in question, starting at 65% and increasing by 10% every quarter to a maximum of 95%.

All indications are the Senator Kelly is on-board with allowing Medicare to negotiate with the pharmaceutical industry, but Senator Sinema hasn’t taken a position.

Because she appears to need a nudge, AzPHA partnered with Protect Our Care on a 60 second radio ad that urges listeners to call Senator Sinema’s office and urge to support the pricing reform parts of the Build Back Better plan.

Here’s a link to that 60 second radio call to action for voters to call Senator Sinema’s office and urge her to vote to allow Medicare to negotiate drug prices: NEW RADIO AD: AZ Health Care Advocate Will Humble Urges Senator Sinema to Let Medicare Negotiate Drug Prices — Protect Our Care

Federal OSHA to Take Over State OSHA (ADOSH) Oversight of Federal Labor Safety Due to Ducey Administration Nonperformance

On Tuesday, the Occupational Safety and Health Administration released a letter stating that they are taking steps to rescind its 1985 decision to allow the Industrial Commission of Arizona to oversee enforcement of federal safety rules via the Arizona State Plan.

Arizona has been considered a “home rule state” meaning that the Arizona Department of Occupational Safety and Health (ADOSH) can  enforce standards even if they varying from OSHA standards as long as certain criteria are met.

In their letter, OSHA alleges that ADOSH isn’t enforcing the Healthcare Emergency Temporary Standard interim final rule which includes masking requirements, and has not met the applicable standard to be permitted to enforce federal safety laws.

Their nonperformance of duties are almost certainly at the direction of Governor Ducey, who stops at nothing to ensure that Arizona does not implement evidence-based interventions to slow the spread of this virus.

Once OSHA rescinds the authority granted to ADOSH, OSHA will have back enforcement authority in Arizona over new COVID-19 and all other worker safety regulations.

CDC Establishes Vaccine Plan for 5-11 Year-Olds: It’s Time for Arizona to Do The Same

Once the CDC’s Advisory Committee on Immunization Practices meets on November 2 and 3rd about the Pfizer pediatric vaccine, HHS will begin releasing the pediatric vaccine to states. 

We’ve been urging the ADHS to develop a plan for deploying the pediatric vaccine for a few weeks now. They issued a blog post last week with a few details, but not a full plan. The CDC has published a detailed outline of their operational plan to quickly distribute and made conveniently and equitably available to families across the country.

HHS has purchased enough vaccine to vaccinate the U.S.’s 28 million kids that are between 5-11 years old. The pediatric vaccine is 1/3 the dose of the adult vaccine and will be coming in smaller boxes that will make it easier for physicians’ offices and other smaller, community-based providers to order what they need (they will come in 10-dose vials in cartons of 10 vials each). It will come with all the supplies that providers need to serve kids (including smaller needles).

The federal plan includes resources for states to stand up vaccination sites at: 1) pediatric offices and other primary care sites; 2) children’s hospitals; 3) pharmacies; and 4) school and community-based clinics (including through FEMA).

The federal government is doing their part, but the state health department will need to do their part to help the county health departments be successful. That means getting clear and detailed information to the county health departments and vaccinators about how they can order and deploy the vaccine.

The bottom line is that pediatric offices and other primary care sites, children’s hospitals, pharmacies, those interested in doing school and community-based clinics (including through FEMA) need clear guidance and a state operational plan. It will take a combination of all those sites operating in tandem to quickly be able to provide vaccination options for Arizona’s 634,000 kids between 5-11 years old.

Delta Wave Status Quo: Steady and High Community Transmission & Swamped Hospitals

View Dr. Gerald’s Full Weekly Report

Arizona continues to have high community transmission and a consistent influx of unvaccinated persons into general ward and ICU beds, pressing hospital teams and impacting care for both COVID & non-COVID patients.

Nineteen percent (1688) of Arizona’s 8754 general ward beds are occupied by mostly unvaccinated COVID-19 patients. Four hundred eighty-two (482, 27%) of Arizona’s 1774 ICU beds are occupied by COVID-19 patients, a 2% increase since last week.

While peak occupancy with this third wave never reached levels seen in the prior two, the base of the wave has the potential to be broader. For example, the summer 2020 and winter 2021 waves saw 57 and 98 days with combined ward and ICU occupancy >2000 patients, respectively.

The current #DeltaDucey wave has had 69 days with a combined occupancy >2000 patients. The persistent base of COVID-19 occupancy has important implications for hospitals as they attempt to meet high season demands from now until February.

View the Full Report